# US 2016/0257972 A1 · Foamy viral vector compositions and methods for the manufacture of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257972 A1
- Document ID: US20160257972A1
- Status: Published application
- Kind: A1
- Application number: 15/041,087
- Filed: 2016-02-11
- Published: 2016-09-08
- Earliest claimed: 2015-03-04
- Applicants: Children's Hospital Medical Center
- Inventors: Johannes C.M. van der Loo; David William Russell; Punam Malik; Md Nasimuzzaman
- Web page: https://patentgrep.com/patent/US20160257972A1

## CPC

- C12N 15/86: Viral vectors
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2740/17043: viral genome or elements thereof as genetic vector
- C12N 2740/17051: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods of preparing FV vector particles. In some aspects, the disclosed methods may include the steps of transfecting a population of eukaryotic cells by contacting said population of eukaryotic cells with one or more transfection reagents to form a transfection mixture, and incubating the transfection mixture to form a transfected cell population; harvesting the FV vector particles from said transfected cell population; purifying the FV vector particles; and concentrating the FV vector particles.

## Claims

### Claim 1

A method of preparing FV vector particles, comprising the steps of:
a. transfecting a population of eukaryotic cells by contacting said population of eukaryotic cells with one or more transfection reagents to form a transfection mixture, and incubating said transfection mixture to form a transfected cell population;
b. harvesting said FV vector particles from said transfected cell population, wherein said harvesting step is carried out about 70 hours to about 100 hours, or about 70 hours to about 90 hours, or about 70 hours to about 80 hours, or about 72 hours to about 75 hours, post-transfection;
c. purifying said FV vector particles;
d. concentrating said FV vector particles.

### Claim 2 (depends on 1)

The method of claim 1 wherein said population of eukaryotic cells are pre-seeded for about 20 to about 30 hours, or about 24 hours, prior to said transfecting step.

### Claim 3 (depends on 1)

The method of claim 1 wherein said pre-seeding is carried out until said population of eukaryotic cells achieves a cell density of from about 1×105 cells/cm2 to about 2×105 cells/cm2 or about 1.8×105 cells/cm2.

### Claim 4 (depends on 1)

The method of claim 1, wherein said pre-seeding step comprises the step of plating eukaryotic cells 1 day prior to PEI transfection with fresh media.

### Claim 5 (depends on 1)

The method of claim 1 wherein said pre-seeding step comprises adding poly-L-lysine in an amount sufficient to pre-coat tissue culture plastic with about 3.5 to about 10 mL per 225 cm2 surface area, preferably at a concentration of about 0.01%.

### Claim 6 (depends on 1)

The method of claim 1 wherein said one or more transfection reagents comprise vector plasmid and a plasmid comprising codon optimized pCiGAGopt.

### Claim 7 (depends on 1)

The method of claim 1 wherein said transfecting step occurs in the presence of about 10% (vol/vol) fetal bovine serum and about 0.4% (vol/vol) PEIPro.

### Claim 8 (depends on 1)

The method of claim 1, wherein said transfecting step occurs in the presence of about 10% fetal bovine serum and calcium phosphate, butyrate, and chloroquine.

### Claim 9 (depends on 1)

The method of claim 1, wherein said transfection mixture is incubated for about 10 to about 20 minutes at ambient temperature (20-24° C.), preferably for about 10 minutes.

### Claim 10 (depends on 1)

The method of claim 1, wherein said transfection mixture is maintained in the initial media until the day of harvest.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pH of said transfection mixture is less than about 8.

### Claim 12 (depends on 1)

The method of claim 1 wherein said FV vector particles is subjected to a filtration step.

### Claim 13 (depends on 1)

The method of claim 1 wherein said transfected cell population is contacted with benzonase at a concentration of from about 50 to about 200 U/mL, preferably about 50 U/mL in the presence of about 10 mM MgCl2 for a period of from about 2 to about 6 hours, preferably about 4 hours prior to a filtration step in one instance, and for 16 to 40 hours prior to vector harvest in another.

### Claim 14 (depends on 1)

The method of claim 1 further comprising the step of isolating said FV vector particles using a heparin column.

### Claim 15 (depends on 1)

The method of claim 1 further comprising the step of concentrating said FV vector particles using tangential flow filtration.

### Claim 16 (depends on 1)

The method of claim 1, further comprising the step of concentrating said FV vector particles, followed by dilution to about 140 mM to about 160 mM, preferably about 150 mM NaCl.

### Claim 17 (depends on 1)

The method of claim 1 further comprising the step of concentrating said FV vector particles using tangential flow filtration.

### Claim 18 (depends on 1)

The method of claim 1 further comprising the step of concentrating said FV vector particles using ultracentrifugation.

### Claim 19 (depends on 1)

The method of claim 1 wherein said FV vector particles are stored at a temperature of about −70° C. to about −90° C., preferably about −80° C. in the presence of DMSO.

### Claim 20 (depends on 1)

The method of claim 1 wherein said FV vector particles are stored frozen in the presence of from about 3 to about 5% DMSO, preferably about 5% DMSO.

### Claim 21

A method of obtaining an increased titer of FV vector particles, comprising the steps of:
a. pre-seeding a population of eukaryotic cells for about 20 to about 30 hours, or about 24 hours, wherein said pre-seeding is carried out until said population of eukaryotic cells achieves a cell density of from about 1×105 cells/cm2 to about 2×105 cells/cm2 or about 1.8×105 cells/cm2;
b. transfecting a population of eukaryotic cells by contacting said population of eukaryotic cells with one or more transfection reagents, wherein said one or more transfection reagents comprise vector and a plasmid comprising codon optimized pCiGAGopt, wherein said plasmid is used at a concentration of about 0.16 to about 10.4 microgram per 75 cm2 culture surface equivalent, preferably 0.65 microgram per 75 cm2 culture surface equivalent to form a transfection mixture, and incubating said transfection mixture to form a transfected cell population;
c. harvesting said FV vector particles from said transfected cell population, wherein said harvesting step is carried out about 70 hours to about 100 hours, or about 70 hours to about 90 hours, or about 70 hours to about 80 hours, or about 72 hours to about 75 hours, post-transfection;
d. purifying said FV vector particles, wherein said purification step comprises use of a media comprising heparin;
e. concentrating said FV vector particles;
f. diluting said FV vector particles to about 150 mM NaCl.
